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Branched-chain amino acids (BCAAs) are essential for critical
metabolic processes; however, recent studies have associated ele-
vated plasma BCAA levels with increased risk of insulin resist-
ance. Using skeletal muscle cells, we aimed to determine whether
continued exposure of high extracellular BCAA would result in
impaired insulin signaling and whether the compound sodium phe-
nylbutyrate (PB), which induces BCAA metabolism, would lower
extracellular BCAA, thereby alleviating their potentially inhibitory
effects on insulin-mediated signaling. Prolonged exposure of elevated
BCAA to cells resulted in impaired insulin receptor substrate 1/AKT
signaling and insulin-stimulated glycogen synthesis. PB significantly
reduced media BCAA and branched-chain keto acid concentrations and
increased phosphorylation of AKT [+2.0±0.1-fold; P < 0.001 versus
without ()PB] and AS160 (+3.2±0.2-fold; P < 0.001 versus PB);
however, insulin-stimulated glycogen synthesis was further reduced
upon PB treatment. Continued exposure of high BCAA resulted in
impaired intracellular insulin signaling and glycogen synthesis, and
while forcing BCAA catabolism using PB resulted in increases in pro-
teins important for regulating glucose uptake, PB did not prevent the
impairments in glycogen synthesis with BCAA exposure.
branched-chain amino acids; in vitro; insulin resistance; phenylbuty-
rate; skeletal muscle
INTRODUCTION
The branched-chain amino acids (BCAAs; leucine, isoleu-
cine, and valine) are essential amino acids that play critical roles
in physiological processes ranging from protein synthesis and
modulation of glucose metabolism to regulation of appetite and
adiposity (11, 18, 29). Recent studies, however, have identified
associations between levels of plasma BCAAs and risk of insu-
lin resistance and type 2 diabetes mellitus (T2DM), although it
is not clear whether BCAAs can cause insulin resistance or
whether increased circulating BCAAs may reflect a conse-
quence of reduced insulin action (9, 21). More detailed investi-
gations into the mechanistic roles that BCAAs and their
intermediary metabolites have in muscle glucose metabolism,
and whether sustained elevations of circulating BCAA can
cause insulin resistance, are therefore necessary.
In terms of the potential underlying mechanisms by which
BCAAs have been linked with insulin resistance, Hernández-
Alvarez et al. (10) observed reduced skeletal muscle expression
of genes involved in BCAAmetabolism in T2DM patients, while
insulin-resistant rats were reported to have an impaired capacity
for BCAA catabolism in skeletal muscle (6). Mice heterozygous
for the BCAA-related enzyme methylmalonyl-CoA mutase
(thereby resulting in dysregulated BCAA metabolism) displayed
increases in muscle triglyceride accumulation and increased
body weight following high-fat feeding (17). Specifically, it has
been proposed that the valine catabolite 3-hydroxyisobutyrate
(3HIB) can promote insulin resistance by promoting lipid accu-
mulation in vivo (14), and cultured myotubes treated with 3HIB
exhibited suppressed insulin signaling and mitochondrial metab-
olism. Elevated plasma 3HIB has also been associated with
future risk of developing T2DM (19). The mechanistic target of
rapamycin (mTOR) pathway has also been proposed as a further
mechanism by which BCAAs may cause insulin resistance,
through inhibition of insulin receptor substrate 1 (IRS-1) via ser-
ine phosphorylation by p70 S6K1 (30). Collectively, these find-
ings support a potential causal role of BCAAs to suppress insulin
sensitivity either directly, or via the products of their catabolism.
Recent studies have focused on strategies aimed at lowering
BCAA as a means of improving insulin resistance. Cummings
et al. (5) observed that reducing dietary BCAA rapidly led to fat
loss and increased glucose tolerance in obese mice, while
BCAA restriction in obese rats improved skeletal muscle insulin
sensitivity and fatty acid metabolism in obese rats (25). In obese
(ob/ob) mice, increasing BCAA catabolic flux using an inhibitor
of BCKA dehydrogenase kinase resulted in reduced levels of
BCAA and decreased insulin resistance (31). However, investi-
gations into the strategy of BCAA restriction or depletion in
humans for improving metabolic health have been lacking. In
patients with Maple Syrup Urine Disease, a disorder of BCAA
metabolism that results in elevations of BCAAs in plasma, the
compound sodium phenylbutyrate (PB) was found to effectively
reduce plasma levels of BCAAs and branched-chain alpha-keto
acids (BCKAs) by increasing flux through the BCKA dehydro-
genase complex (4). PB, which is converted into the active
metabolite phenylacetate in vivo, combines with glutamate to
form phenylacetylglutamine, which is then disposed of in the
urine (4). In a study of overweight and obese males, PB admin-
istration was demonstrated to partially improve lipid-induced
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insulin resistance, although circulating BCAA concentrations
were not measured in this study (26). These findings suggest
that treatment with PB could provide benefits for metabolic dis-
orders such as insulin resistance in humans, potentially through
the promotion of BCAA intermediary metabolism (moreover, a
therapeutic approach may be better tolerated and have greater
compliance compared with a dietary approach).
Based on the combined evidence to date, the aims of the pres-
ent study were to investigate the mechanistic links between
BCAA, intracellular insulin signaling, and muscle glucose me-
tabolism. Using an in vitro skeletal muscle cell model, we
hypothesized that lowering extracellular BCAA concentrations
using the compound PB would effectively reduce molecular
markers of insulin resistance under conditions of sustained
increases in media BCAAs by accelerating their catabolism and
reducing concentrations of BCAAs and their downstream
metabolites thereby alleviating their inhibitory effects on insulin
signaling and substrate metabolism.
METHODS
C2C12 cell culture experiments. Murine C2C12 myoblasts (pas-
sage 6–8; ECACC, Salisbury, UK) were cultured at 37C and 5%
CO2 in minimum essential medium alpha (MEMa; Thermo Fisher
Scientific) supplemented with 10% (vol/vol) fetal bovine serum
(FBS) and 1% (vol/vol) antibiotic-antimycotic solution (all from
Sigma-Aldrich, UK). Cells were seeded onto six-well multidishes
(Nunclon Delta; Thermo Fisher Scientific), and once cells reached
90% confluency, differentiation was induced by changing the me-
dium to MEMa containing 2% (vol/vol) horse serum. A media
change was carried out every 48 h, and experiments were performed
on days 4–5 postinduction of differentiation.
For measuring the effects of PB under basal and insulin-stimulated
conditions, and with normal (1) or elevated (4) media BCAA, 4
days after induction of differentiation, myotubes were treated for 48 h
with normal (1) or elevated (4) media BCAA concentrations. In the
MEMa used, unsupplemented BCAA media concentrations were all
0.4 mM, according to the manufacturer. For basal experiments, cells
were treated with or without 7.5 mM PB for 6 h (in the range of previ-
ously used doses, e.g., Ref. 3, 12) after the 48-h period. For insulin-
stimulated experiments, cells were treated with or without 7.5 mM PB
and then after 3 h, the media were replaced with fresh media supple-
mented with insulin (to a final concentration of 300 nM) and cells were
collected after a further 3 h (n = 6 replicates for each treatment group).
Where media were replaced, 1 and 4 BCAA concentrations were
maintained in the respective treatment groups, as well as PB treatments
(such that cells were exposed to 6-h PB in both basal and insulin-stimu-
lated experiments). Media were collected and cells were harvested in
homogenization buffer (50 mM Tris·HCl, pH7.5, 1 mM EDTA, 1 mM
EGTA, 10 mM b-glycerophosphate, 50 mM NaF, and complete prote-
ase inhibitor cocktail tablet; Roche, UK) for immunoblotting analysis
and measurement of intracellular glycogen concentrations (see below).
Measurement of media amino acids and branched-chain alpha-
keto acids. Cell culture media (100 μL) with 10-μL internal standard (a
mix of stable isotopically labeled amino acids) added were purified by
passing through H+ dowex resin columns and were eluted into 2 mol/L
NH4OH and dried down. Amino acids were derivatized to their tert-
butyldimethylsilyl (tBDMS) esters, and concentrations were deter-
mined using gas chromatography-mass spectrometry (GC-MS; Trace
1300-ISQ, Thermo Scientific) against a standard curve of known
concentrations.
Media concentrations of the BCKA [alpha-ketoisocaproic acid
(KIC); alpha-keto-beta-methylvaleric acid (KMV), and alpha-ketoiso-
valeric acid (KIV)] were measured by mixing 100 μL of cell culture
media with alpha-ketovaleric acid as internal standard, deproteinising
using ice-cold ethanol and drying down under nitrogen. The BCKAs
were derivatized to quinoxalinol-t-BDMS derivatives, and concen-
trations were determined using GC-MS (Trace 1300-ISQ, Thermo
Scientific) with a standard curve of known concentrations of each
BCKA.
Western blot analysis. Samples were lysed by repeatedly passing
through gel-loading pipette tips, and lysates were centrifuged at
13,000 g for 10 min. Ten micrograms of protein were loaded onto
Criterion XT 12% Bis-Tris gels (Bio-Rad, UK), and samples were
electrophoresed at 200 V for 1 h. Sample transfer to PDVF mem-
branes was performed at 100 V for 45 min, and membranes were
blocked in 5% (wt/vol) milk for 1 h at room temperature. Primary
antibody incubation was carried out overnight at 4C with the following
antibodies: AKT Ser473 (no. 4060), AS160 Thr642 (no. 8881), and
IRS-1 Ser1101 (no. 2385; Cell Signaling Technology, UK). After anti-
body incubations, membranes were washed with 1 TBS-Tween and
incubated with anti-rabbit horseradish peroxidase (HRP)-conjugated
secondary antibody (no. 7074; Cell Signaling Technology, UK; 1:2,000
dilution) for 1 h at room temperature. After further washing with TBS-
Tween, bands were detected using Chemiluminescent HRP substrate
(Millipore EMD) with a Chemidoc XRS imaging system (Bio-Rad,
UK). Staining of the membrane with Coomassie brilliant blue was used
for total protein normalization.
Measurement of cellular glycogen. Cellular glycogen concentrations
were determined in samples from the insulin stimulation experiments
using the colorimetric Glycogen Assay Kit II (Abcam), according to the
manufacturer instructions. Glycogen levels were normalized to total
protein content of each sample.
Statistical analyses. Data were analyzed using two-way ANOVA
(using Tukey’s multiple comparison post hoc test) to evaluate differen-
ces between treatment groups. P < 0.05 was considered as statistically
significant. All data are presented as means ±SE.
RESULTS
Effects of elevated BCAA on media amino acid and alpha-
keto acid concentrations in C2C12 myotubes. For initial experi-
ments, we sought to assess how sustained elevations in media
BCAA concentrations would affect glycogen synthesis under
basal and insulin-stimulated conditions, first measuring the
impact of sustained high BCAA on concentrations of other
amino acids and alpha-keto acids in the media. Under normal
BCAA (1) conditions (i.e., standard in the supplied media), in-
sulin/feeding resulted in increases in media BCAA concentra-
tions as well as glutamine and glutamate (Table 1), indicative of
the replenishment in substrates postmedia change (compared
with the basal condition, which was 48 h postmedia change).
Elevating media BCAA (4) did not have any overall effects
on concentrations of media glutamine or glutamate; however,
elevated media BCAA caused a reduction in alanine concentra-
tions (P < 0.001 versus 1 BCAA for basal conditions, P <
0.05 versus 1 BCAA for insulin-stimulated conditions; Table
1). Concentrations of media BCKA were significantly increased
under conditions of high BCAA (P < 0.05 main effect by
ANOVA; Table 2).
Effects of elevated BCAA on glycogen content and insulin
signaling in C2C12 myotubes. Cells were analyzed for glyco-
gen content as well as phosphorylation of proteins important
in mediating insulin signaling pathways to assess the impact
of BCAA exposure levels (i.e., 1 and 4) upon insulin-sig-
naling and glycogen content. Under basal conditions, 4
BCAA resulted in decreased glycogen content (5% versus
1 BCAA; P < 0.05; Fig. 1A), while insulin-stimulated
increases in muscle glycogen content were suppressed under
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high BCAA conditions (Fig. 1A). Overall, 4 BCAA conditions
resulted in lower phosphorylation of AKT (32% versus 1
BCAA under basal conditions; P < 0.05; 30% versus 1
BCAA under insulin-stimulated conditions; P < 0.05; Fig. 1B).
Under conditions of 4 BCAA, AS160 phosphorylation was
reduced under basal conditions (44% versus 1 BCAA; P <
0.01), while under insulin-stimulated conditions, there was no dif-
ference in AS160 phosphorylation compared with 1 BCAA con-
ditions (Fig. 1C). Under insulin-stimulated conditions, increased
media BCAA resulted in increases in IRS-1 serine phosphoryla-
tion relative to normal BCAA conditions (Fig. 1D).
Effects of PB treatment on media amino acid and keto acid
concentrations in C2C12 myotubes. To investigate whether
accelerated BCAA catabolism using PB could restore the
impairments in insulin signaling and glucose metabolism with
high BCAA, the impact of PB treatment was assessed under ba-
sal conditions or following a feed supplemented with insulin,
with prior 48-h treatment with high concentrations of media
BCAA. Under high BCAA conditions (4), there were signifi-
cant reductions in media concentrations of valine with PB treat-
ment under basal [1,101± 24 versus 973± 16 μmol/l, P < 0.05
versus without ()PB] and insulin-stimulated (1,457 ± 79 versus
1,146± 14 μmol/l, P < 0.001 versus PB) conditions, while
leucine (1,377 ± 90 versus 1,105± 30 μmol/l, P < 0.01 versus
PB) and isoleucine (1,533± 85 versus 1,323 ± 36 μmol/l, P <
0.05 versus PB) were reduced with PB treatment, under insu-
lin-stimulated conditions only (Fig. 2, A–C). Under 4 BCAA
conditions, PB did not significantly alter media concentrations
of KIC, KIV, or KMV either with basal or insulin-stimulated/
fed conditions (Fig. 2, D–F).
Effects of PB treatment on glycogen content and insulin sig-
naling in C2C12 myotubes. Under conditions of elevated
BCAA, there was a decrease in glycogen concentration follow-
ing PB treatment under basal (0.070 ± 0.0008 versus 0.074±
0.0007 μg/μg protein; P < 0.05 versus PB) and insulin-stimu-
lated conditions (0.063 ± 0.0003 versus 0.074 ± 0.0013 μg/μg
protein; P < 0.001 versus PB; Fig. 3A). AKT phosphorylation
was elevated with PB under high BCAA conditions, both in the
basal (2.0 ± 0.1-fold versus PB; P < 0.001) and insulin-stimu-
lated (2.0± 0.1-fold versus PB; P < 0.001) state (Fig. 3B),
while AS160 Thr642 phosphorylation was also significantly
increased by PB treatment (3.2 ± 0.2-fold versus PB in basal
conditions; P < 0.001; Fig. 3C). IRS-1 Ser1101 phosphoryla-
tion was not significantly altered by PB treatment under insulin-
stimulated or basal conditions (Fig. 3D).
DISCUSSION
To date, the role of BCAA in mediating insulin resistance and
metabolic dysregulation in T2DM remains unclear, since
BCAAs are known to be important in a wide range of metabolic
pathways and are critical regulators of protein turnover and fuel
metabolism, but elevated circulating BCAAs have recently been
significantly correlated with insulin resistance in healthy indi-
viduals and in metabolic disorders such as T2DM (1, 2, 8, 27).
The aims of the present study therefore were to investigate the
mechanistic links between BCAAs, intracellular insulin signal-
ing, and muscle glucose metabolism, using an in vitro skeletal
muscle model. We hypothesized that lowering extracellular
BCAAs by accelerating their catabolism (using the compound
PB), thereby reducing concentrations of BCAAs and their
downstream metabolites, would alleviate their inhibitory effects
on insulin signaling and substrate metabolism. We observed that
exposing the cells to sustained increases in extracellular BCAA
caused impairments in insulin-stimulated glycogen synthesis
and intracellular insulin signaling. Interestingly, while murine
C2C12 myotubes treated with PB had lowered media BCAA
concentrations and increased molecular markers of proteins that
regulate glucose uptake (potentially suggestive of improved in-
sulin sensitivity), cells exhibited no improvements in insulin-
mediated glycogen synthesis.
Impact of elevated BCAA on insulin signaling and glycogen
content in C2C12 myotubes. The present study was motivated
by recent observations that higher concentrations of BCAA
were associated with insulin resistance and an increased risk
of T2DM in adults (1, 8) and that targeting catabolism of
BCAA may reduce levels of BCAA, and thereby decrease in-
sulin resistance (31). In a group of subjects with T2DM,
higher concentrations of BCAA were associated with homeo-
static model assessment of insulin resistance (HOMA-IR)
and an increased risk of T2DM (8). Some studies however
have demonstrated that BCAA or leucine supplementation
can improve insulin sensitivity in individuals with T2DM
(23) and glucose tolerance in patients with chronic liver
Table 1. Media amino acid concentrations in C2C12 myo-
tubes with or without elevated media branched chain amino
acids and insulin treatment
1 BCAA 4 BCAA
Basal INS/feed Basal INS/feed
Val 277 ± 8 405 ± 37** 1,101 ± 24### 1,457 ± 79**###
Leu 262 ± 8 392 ± 15*** 1,248 ± 29### 1,344 ± 64###
Ile 377 ± 7 476 ± 32* 1,468 ± 37### 1,499 ± 56###
BCAA (sum) 916 ± 23 1,275 ± 78** 3,818 ± 75### 4,334 ± 214###
Gln 1,505 ± 185 2,093 ± 174* 1,449 ± 57 1915 ± 108**
Glu 127 ± 8 507 ± 26*** 119± 3 460± 33***
Ala 521 ± 38 382 ± 41* 173± 29### 250± 26#
Data are means ± SE and units are mmol/l. C2C12 myotubes were treated
for 48 h with or without elevated (4) media branched chain amino acids
(BCAAs), and then cells were treated for 3 h with or without feeding plus in-
sulin (INS; 300 mM; n = 5–6 per group). Media were analyzed for concentra-
tions of selected amino acids. *P < 0.05 vs. basal, **P < 0.01 vs. basal,
***P < 0.001 vs. basal. #P < 0.05 vs. 1 BCAA, ###P < 0.001 vs. 1
BCAA.
Table 2. Media alpha-keto acid concentrations in C2C12
myotubes with or without elevated media branched chain
amino acids and insulin treatment
1 BCAA 4 BCAA
Basal INS/feed Basal INS/feed
KIC 34 ± 1 24 ± 4* 210 ± 18### 67 ± 8***##
KMV 40± 1 17 ± 3*** 166 ± 10### 61 ± 10***##
KIV 19± 1 11 ± 2** 79 ± 5### 27 ± 3***##
Data are means ± SE and units are mmol/l. C2C12 myotubes were treated
for 48 h with or without elevated (4) media branched chain amino acids
(BCAAs), and then cells were treated for 3 h with or without feeding plus in-
sulin (INS; 300 mM; n = 5 per group). Media were analyzed for concentra-
tions of selected alpha-keto acids. KIC, alpha-ketoisocaproic acid (KIC);
KMV, alpha-keto-beta-methylvaleric acid; KIV, alpha-ketoisovaleric acid.
*P < 0.05 vs. basal, **P < 0.01 vs. basal, ***P < 0.001 vs. basal. ##P <
0.01 vs. 1 BCAA, ###P < 0.001 vs. 1 BCAA.
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disease (15, 20). BCAA supplementation is also beneficial to
energy expenditure, through brown adipose tissue utilizing
BCAA in mitochondria, thus promoting BCAA clearance
(28). These findings highlight the uncertainty that has sur-
rounded the role of BCAA, and their metabolites, in the regu-
lation of insulin resistance and metabolic dysfunction.
In this study, we were able to develop a model in vitro that
allowed us to directly examine the impact of increased/
decreased extracellular BCAA on the regulation of glycogen
content in skeletal muscle. Exposure of myotubes for 48 h with
elevated BCAA resulted in marked increases in levels of BCKA
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Fig. 1. Glycogen content and insulin-related signaling changes in C2C12 myotubes with or without elevated media branched chain amino acids (BCAAs) and insulin
treatment. C2C12 myotubes were treated for 48 h with or without elevated (4) media BCAA, and then cells were treated for 3 h with or without feeding/insulin
(300 mM; n = 6 per group). Cells were analyzed for glycogen content (normalized against total protein; A) and phosphorylation of AKT (Ser473; B), AKT substrate
of 160 kDa (AS160; Thr642; C), and insulin receptor substrate 1 (IRS-1; Ser1101;D). Triangles represent individual data points. **P< 0.01 vs. basal, ***P< 0.001












































































































































Fig. 2. Media amino acid (A–C) and alpha-keto acid (D–F) concentrations following phenylbutyrate (PB) treatment under conditions of elevated branched-chain
amino acids (BCAAs). C2C12 myotubes were treated for 48 h with elevated (4) media BCAA, and then cells were treated for 3 h with or without 7.5 mM PB and
then a further 3 h with or without feeding plus insulin (300 mM; n = 5–6 per group). Media were analyzed for concentrations of selected amino acids and alpha-keto
acids. KIC, alpha-ketoisocaproic acid (KIC); KMV, alpha-keto-beta-methylvaleric acid; KIV, alpha-ketoisovaleric acid. Triangles represent individual data points.
**P< 0.01 vs. basal, ***P< 0.001 vs. basal (by ANOVA). #P< 0.05 vs. without ()PB, ##P< 0.01 vs.PB, ###P< 0.001 vs.PB (by ANOVA).
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up of intermediates in the BCAA catabolism due to excess sub-
strates or potentially that there were impairments in BCAA ca-
tabolism. This is in line with previous findings that insulin-
resistant rats exhibited an impaired capacity for BCAA catab-
olism in skeletal muscle (6) and supports the suggestion that
targeting catabolism of BCAA may reduce levels of BCAA
and thereby decrease insulin resistance in these settings (31).
How the elevated BCAA may have impacted on pyruvate uti-
lization, and thereby ATP production and muscle mitochon-
drial metabolism, was not assessed in our study but remains a
valuable area of future study. In these experiments, we sought
to measure how sustained elevations in media BCAA concen-
trations would affect glycogen content under basal and insu-
lin-stimulated conditions, and at the molecular level, we
examined the effects of high BCAA on intracellular signal-
ing. Under basal and fed conditions, AKT activation was
decreased with 4 BCAA, suggesting an impairment in activity
due to increased BCAA. Under basal conditions, AS160 phos-
phorylation appeared to be decreased with 4 BCAA, while this
decrease was not observed under insulin-stimulated conditions,
indicating that elevated BCAA had different impacts on the reg-
ulation of glucose uptake under basal and insulin-stimulated set-
tings. It is unclear why AS160 phosphorylation was not induced
by insulin under normal BCAA conditions but could feasibly
reflect an early but transient stimulation by insulin that was
restored to baseline values by 3 h postfeed. IRS-1 serine phos-
phorylation was increased following prolonged high BCAA
administration under insulin-stimulated conditions, which to-
gether indicates an inhibitory impact on insulin-regulated path-
ways. These observations are in agreement with previous data
proposing that BCAA may cause insulin resistance through inhi-
bition of IRS-1, potentially downstream of mTOR activation
(30). High levels of BCAA also appeared to inhibit insulin-
stimulated increases in glycogen content, suggesting that,
along with changes in intracellular insulin signaling, sus-
tained increases in BCAA had negative impacts on insulin
sensitivity at the level of glycogen synthesis. Overall, the
model used in the present study allowed us to directly assess
the impact of increased/decreased extracellular BCAA on the
regulation of glucose utilization in skeletal muscle cells.
Impact of PB treatment on insulin signaling and glycogen
content in C2C12 myotubes. Subsequent experiments addressed
whether accelerating BCAA metabolism under conditions of ele-
vated BCAA, using the compound PB, would lower extracel-
lular BCAA, thereby alleviating their inhibitory effects on
insulin-mediated signaling. Treatment with the compound PB
[as expected from previous studies (12)] significantly reduced
media concentrations of BCAA under conditions of elevated
BCAA (under fed conditions). Under conditions of high
BCAA, while PB was able to suppress BCAA concentrations,
elevations in BCKA were not significantly altered, which
could indicate some impairments in the BCAA catabolic
pathways under conditions of elevated BCAA. Thus, in our
present model of BCAA-induced muscle insulin resistance,
the build-up of extracellular BCKA was not prevented by PB.
To explore the mechanistic links between BCAA catabo-
lism and insulin signaling pathways, we measured selected
molecular targets known to be important in regulating glu-
cose homeostasis. PB treatment has previously been reported
to accelerate glucose uptake and glycogen synthesis in mus-
cle (13), demonstrating one mechanism by which PB could
provide benefits in terms of improving insulin sensitivity.
Treatment with PB increased AKT phosphorylation (i.e., acti-
vation) in the high BCAA condition, while with elevated
BCAA, PB further increased AS160 activation, both of which
are critical steps in the translocation of glucose transporter 4
(GLUT4) transporters to the cell surface and which would be
predicted to increase glucose uptake (24). These findings are
in agreement with previous studies reporting increased glu-
cose uptake in response to PB administration (13), although
in contrast to the work of Hu et al., our findings were indica-
tive of increased glucose uptake into muscle cells during con-
ditions of BCAA-induced insulin resistance. These findings
suggest that increasing catabolic flux of BCAA could have
beneficial effects on insulin-resistant skeletal muscle in terms
of stimulating glucose uptake. Unexpectedly, PB treatment
decreased glycogen content under high BCAA conditions. It is
not clear why such differences may be observed compared with
previous studies (13) but could reflect differences in experimen-
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Fig. 3. Glycogen content and insulin-related signaling change following phenylbutyrate (PB) treatment under conditions of elevated branched-chain amino acids
(BCAA). C2C12 myotubes were treated for 48 h with elevated (4) media BCAA, and then cells were treated for 3 h with or without 7.5 mM PB and then a further
3 h with or without feeding plus insulin (300 mM; n = 6 per group). Cells were analyzed for glycogen content (normalized against total protein; A) and phosphoryla-
tion of AKT (Ser473; B), AKT substrate of 160 kDa (AS160; Thr642; C), and insulin receptor substrate 1 (IRS-1; Ser1101; D). Triangles represent individual data
points. *P< 0.05 vs. basal, **P< 0.01 vs. basal, ***P< 0.001 vs. basal (by ANOVA). #P< 0.05 vs. without ()PB, ###P< 0.001 vs.PB (by ANOVA).
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shown to stimulate fatty acid oxidation and cellular respiration
in cultured cells (17); therefore, it is possible that increased glu-
cose uptake, along with decreased glycogen synthesis with PB
treatment, could reflect a stimulation of cellular glucose metabo-
lism. These changes could also be linked to alterations in metab-
olism caused by PB, since there are indications that PB may
influence regulation of the pyruvate dehydrogenase complex
(PDC) (7). It is also possible that some of the observed changes
occurred independently of BCAA, since PB has also been shown
to influence other biological pathways, including inhibition of his-
tone deacetylases (16), which could influence glucose utilization.
In summary, previous findings of enhanced flux through PDC,
and the present observations of enhanced molecular regulators of
glucose uptake, indicate that increased muscle glucose utilization
may have occurred as a result of PB administration, likely driven
by multiple factors, which include BCAA catabolism.
Study limitations and future perspectives. Intracellular levels
of BCKAwere not measured in these experiments, which would
have given further insight into downstream impacts of elevated
BCAA on muscle cells, since one mechanism by which BCAAs
are thought to cause insulin resistance is via inhibitory effects of
3HIB on insulin signaling and fatty acid metabolism (14).
While AS160 phosphorylation has been reported to be a key
step in GLUT4 translocation to the cell surface (24), which was
used in the present study as an indirect estimation of glucose
uptake, direct measures of glucose uptake would have strength-
ened our findings. Measurements of fatty acid metabolites [as
regulators of BCAA catabolism (22)] in the present study would
have also allowed us to further investigate the potential links
between fatty acid metabolism and insulin resistance due to
BCAA. Measuring media BCKA levels in the present study,
which would have originated from the cells, did however give
us some insights into BCAA metabolism with PB treatment and
BCAA exposure levels. For example, under conditions of high
BCAA, while PB reduced BCAA concentrations, elevations in
BCKA were unaltered, which could indicate some impairments
in the BCAA catabolic pathways under conditions of elevated
BCAA. Of note was the observation that sustained increases in
media BCAA have little influence on basal glutamine and gluta-
mate concentrations, while alanine levels were significantly
lower compared with 1 BCAA. While our model in the pres-
ent study aimed to focus on muscle-specific effects of BCAA on
insulin resistance, undoubtedly more detailed analysis, includ-
ing investigation of the role of muscle-liver and/or muscle-adi-
pose cross talk in the relationship between BCAA and insulin
resistance, will ultimately be required to fully understand the
full impact of sustained increases in BCAA on amino acid/sub-
strate metabolism.
In conclusion, in the present study we demonstrated that con-
tinued exposure of high BCAA to skeletal muscle cells in vitro
resulted in impaired intracellular insulin signaling and insulin-
stimulated glycogen synthesis, and while PB treatment acceler-
ated BCAA catabolism and activated proteins important for
mediating cellular glucose uptake, BCAA catabolism caused
further reductions in insulin-stimulated glycogen synthesis.
These observations could argue against the use of targeting
BCAA catabolism for lowering BCAA concentrations in condi-
tions of insulin resistance in vivo. The findings presented con-
tribute to further insight into regulation of glucose metabolism
by BCAA in muscle, and future work using preclinical and
human subjects (both healthy volunteers and patient populations)
will be required to further increase our understanding of the ther-
apeutic potential of targeting BCAA catabolism in conditions of
metabolic dysfunction such as T2DM.
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